However, possibly due to the existence of more effective therapies as well as less conclusive animal data, development activities related to MCHR1 antagonists within the depression/anxiety indication have always lagged behind obesity [19]. Here, MCHR1 is linked to obesity due to melanocortin 4 receptor deficiency.